Survival with Cemiplimab in Recurrent Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, February 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 98 news outlets
blogs: 2 blogs
twitter: 50 X users

facebook: 1 Facebook page
guideline: 9 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 265 Mendeley

So far, Altmetric has seen 54 X posts from 50 X users, with an upper bound of 1,262,432 followers.

Survival with Cemiplimab in Recurrent Cervical Cancer | NEJM https://t.co/We1jD5B6Wn

今日の抄読会📖 再発子宮頸癌に対する抗PD-1のCemiplimab 日本でももうすぐ使えそう。 PD-L1 statusに依存せずに生存期間を延長する🍀 TCBev不応となった再発頸癌のsecond lineの選択肢がどんどん増えてくる✨ Survival with Cemiplimab in Recurrent Cervical Cancer | NEJM…

#Survival with #Cemiplimab in #Recurrent #Cervical #Cancer | #NEJM https://t.co/DRhITKqrnV

RT @davidhenrymd: Survival with Cemiplimab in Recurrent Cervical Cancer. An impressive phase 3 trial showing that the addition of this PDL…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 50 additional X posts.